Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Qua...
April 22 2020 - 1:38PM
Interpace (IDXG) announced today that it will release its financial
results for the fourth quarter and full year 2019 this afternoon.
Company management will host a conference call and webcast to
discuss its financial results and provide a general business update
at 5:00 pm today, Wednesday April 22, 2020 at 5:00 p.m.
Eastern time.
The conference call can be accessed as
follows:
Date and Time: Wednesday,
April 22, 2020 at 5:00 p.m. ETDial-in Number
(Domestic): +1 (877) 407-9716Dial-in Number
(International): +1 (201)
493-6779Confirmation
Number: 137025801Webcast Access:
http://public.viavid.com/index.php?id=139473
Following the conclusion of the conference call,
a replay will be available through May 6, 2020. The live,
listen-only webcast of the conference call may also be accessed by
visiting the Investors section of the Company’s website at
www.interpacediagnostics.com. A replay of the webcast will be
available following the conclusion of the call and will be archived
on the Company’s website for 90 days.
About Interpace Biosciences
Interpace Biosciences is a leader in enabling
personalized medicine, offering specialized services along the
therapeutic value chain from early diagnosis and prognostic
planning to targeted therapeutic applications.
Clinical services, through the Interpace
Diagnostics division, provide clinically useful molecular
diagnostic tests, bioinformatics and pathology services for
evaluating risk of cancer by leveraging the latest technology in
personalized medicine for improved patient diagnosis and
management. Interpace has four commercialized molecular tests and
one test in a clinical evaluation process (CEP): PancraGEN® for the
diagnosis and prognosis of pancreatic cancer from pancreatic cysts;
ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules
utilizing a next generation sequencing assay; ThyraMIR® for the
diagnosis of thyroid cancer from thyroid nodules utilizing a
proprietary gene expression assay; and RespriDX® that
differentiates lung cancer of primary versus metastatic origin. In
addition, BarreGEN® for Barrett’s Esophagus, is currently in a
clinical evaluation program whereby we gather information from
physicians using BarreGEN® to assist in positioning the product for
full launch, partnering and potentially supporting reimbursement
with payers.
Pharma services, through the Pharma Solutions
Division, provides pharmacogenomics testing, genotyping,
biorepository and other customized services to the pharmaceutical
and biotech industries. Pharma services also advance personalized
medicine by partnering with pharmaceutical, academic, and
technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs with the goal of
delivering safer, more effective drugs to market more quickly, and
improving patient care.
For more information, please visit Interpace
Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement, including
the potential adverse impact of the Coronavirus (COVID-19)
pandemic, our history of operating losses and the limited revenue
generated by our clinical and pharma solutions customers,
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company's most
recent Annual Report on Form 10-K filed on April 22, 2020. Because
of these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
Contacts: Investor Relations
Edison Group Joseph Green (646) 653-7030 jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024